Evidence map›Paper›PMID 22029936›Full record

ArticleVirology2011

The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization.

Erica Lovelace, Hengyu Xu, Catherine A Blish, Roland Strong, Julie Overbaugh

Open access · greenAbstract read
In one paragraph

Article in Virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Erica LovelaceDivisions of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Hengyu Xu
Catherine A Blish
Roland Strong
Julie Overbaugh
Fred Hutch Cancer Center · US

Funding

VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Interdisciplinary Tranining in Cancer ResearchT32CA080416 · NCI · UNIVERSITY OF WASHINGTON · PI STODDARD, BARRY L. · 1998 to 2023
$9.7M
Characterization of HIV-1 Antibody Responses in Chronically Infected WomenR01HD058304 · NICHD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 2007 to 2011
$2.3M
NCI NIH HHS T32 CA080416NCI NIH HHS T32 CA80416NIAID NIH HHS T32 AI007140NIAID NIH HHS T32 AI07140NICHD NIH HHS R01 HD058304
6 · The paper itself

Abstract

The detailed interactions between antibodies and the HIV-1 envelope protein that lead to neutralization are not well defined. Here, we show that several conservative substitutions in the envelope gp41 led to a ~100 fold increase in neutralization sensitivity to monoclonal antibodies (MAbs) that target gp41: 4E10 and 2F5. Substitution at position 675 alone did not impact neutralization susceptibility to MAbs that recognize more distal sites in gp120 (b12, VRC01, PG9). However, changes at position 675 in conjunction with Thr to Ala at position 569 increased the neutralization sensitivity to all gp41 and gp120 MAbs and plasma, in some cases by more than 1000-fold. Interestingly, the T569A change had a dramatic effect on b12 binding, but no effect on neutralization sensitivity. This finding suggests that antibody neutralization may occur through a multi-step pathway that includes distinct changes in envelope conformation that may affect binding but not neutralization susceptibility.

Indexed as

Amino Acid SubstitutionAntibodies, MonoclonalAntibodies, NeutralizingAntibody AffinityAntibody SpecificityHEK293 CellsHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41HumansProtein Structure, TertiarySequence Analysis, ProteinAntibodies, MonoclonalAntibodies, NeutralizingHIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41

Identifiers

PMID22029936
PMCPMC3249416
OpenAlexW2095243290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.